Navigation Links
BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
Date:5/12/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, May 12 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 5th Annual Global Healthcare Conference in Monte Carlo, Monaco.

WHEN: Monday May 19th at 11:25 AM (Local Time)

WHERE: Le Meridien Beach Plaza Hotel, Monte Carlo

About Rodman and Renshaw Global Healthcare Conference

----------------------------------------------------- The Conference will include presentations by companies, as well as experts from the medical, scientific and investment communities. The Conference will be attended by investors, venture capitalists, company executives, scientists and other industry leaders.

For more information visit http://www.rodmanandrenshaw.com/conferences?id=18

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com. '/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
(Date:8/16/2014)... NY (PRWEB) August 16, 2014 ... industry provide guidance and advisory services to ... and technical issues. Industry services are highly diverse ... Therefore, industry services range from geological and geophysical ... plans. “Consequently, over the past five years, the ...
Breaking Biology Technology:iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3
... Holdings, Inc. (NYSE: ZMH ; SWX: ZMH) announced today ... broadcast live over the Internet on Thursday, July 23, 2009, at ... results will be made available at 7:00 a.m. the morning of ... be accessed via Zimmer,s Investor Relations website at ...
... Pa. and NEWTON, Mass., June 30 Microfluidics, ... (OTC Bulletin Board: MFLU), and Particle Sciences Inc. ... biopharmaceutical companies leverage the most advanced and reliable ... and commercialize Active Pharmaceutical Ingredients (APIs). , ...
... June 30 Hospira, Inc. (NYSE: HSP ... today announced agreements with MedAssets on intravenous (I.V.) solutions ... agreement for infusion devices. The five-year MedAssets agreements are ... and equipment, and July 1, 2009, for infusion devices. ...
Cached Biology Technology:Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 2Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 3Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2
(Date:8/19/2014)... MA -- MIT chemical engineers have devised a new ... are released slowly over a few weeks. When applied ... the body to rapidly form new bone that looks ... type of coated scaffold could offer a dramatic improvement ... involves transplanting bone from another part of the patient,s ...
(Date:8/19/2014)... today,s crocodiles colonised the seas during warm phases and ... Anglo-French study which establishes a link between marine crocodilian ... period of more than 140 million years. , ... Universit de Lyon, France and formerly from the University ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals that ...
(Date:8/19/2014)... A team of UTSA researchers has been awarded a ... Technology and Training (NCPTT), an office of the National ... The grant will fund a one-year study of the ... of historic homes in hot, humid climates. , Radiant ... or attics that reflect heat back, thereby reducing the ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3Evolution of marine crocodilians constrained by ocean temperatures 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Angeles New evidence from the University of Southern California ... that help compile small bits of information in order to ... professor of psychology in the area of brain and cognitive ... Public Library of Science journal, PLoS ONE. It ...
... MA--Boston University School of Medicine (BUSM) will present The Sixth ... 14, 2007 at noon. The annual lecture is in honor ... in BUSMs Pulmonary Center. Kim Hanson, along with her ... the second plane that struck the World Trade Center on ...
... University of Oregon has received a $1.6 million grant ... effects of exposure to precisely engineered nanoparticles that are ... three-year grant from the Keck Foundations medical research program ... Andy Berglund, all UO professors of chemistry; UO biology ...
Cached Biology News:Shape encoding may start in the retina 2Lecture to honor victim of Sept. 11 tragedy 2Keck Foundation funds study of biological interactions with nanomaterials 2
...
... measures NOS activity by monitoring the conversion ... is simple, sensitive, and specific for NOS ... crude and purified enzyme preparations. The kit ... total reactions. Radiolabeled arginine and NADPH are ...
Human TSLP MAb (Clone 258136)...
Human Complement Component C5a MAb (Clone 295003)...
Biology Products: